A study of AZD4635 with durvalumab and with cabazitaxel and durvalumab in patients with mCRPC.

Trial Identifier: D8731C00002
Sponsor: AstraZeneca
Collaborator:
Parexel International
NCTID:: NCT04495179
Start Date: August 2020
Primary Completion Date: November 2021
Study Completion Date: August 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
English (UK) Translation
Spanish Translation
Spanish (United States) Translation
French (Belgium) Translation
French Translation
Korean Translation
Dutch (Belgium) Translation

Trial Locations

Country Location
BE Brasschaat, BE, 2930
BE Gent, BE, 9000
ES Barcelona, ES, 8035
ES Barcelona, ES, 08041
ES Hospitalet deLlobregat, ES, 08907
ES Madrid, ES, 28034
FR Bordeaux, FR, 33076
FR Villejuif, FR, 94805
KR Goyang-si, KR, 10408
KR Seoul, KR, 06591
KR Seoul, KR, 06351
US, CA Sacramento, CA, US, 95817
US, FL Tampa, FL, US, 33612
US, GA Atlanta, GA, US, 30318
US, MO Saint Louis, MO, US, 63110
US, NC Winston-Salem, NC, US, 27157